PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer.
about
Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1.Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab.The presence of PD-1 positive tumor infiltrating lymphocytes in triple negative breast cancers is associated with a favorable outcome of disease.Novel treatment strategies for patients with HER2-positive breast cancer who do not benefit from current targeted therapy drugsTrastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers
P2860
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer.
@en
type
label
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer.
@en
prefLabel
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer.
@en
P2093
P2860
P356
P1433
P1476
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer.
@en
P2093
Andreas D Hartkopf
Bernhard Krämer
Christina B Walter
Eva-Maria Grischke
Sara Y Brucker
P2860
P304
P356
10.1159/000453569
P577
2016-12-08T00:00:00Z